Pharming Group NV · EURONEXT:PHARM
Pharming Group NV — HollandBIO (September 2017)
24 slides from Pharming Group NV's conference presentation, September 2017
Slide 1: Pharming Group NV
Pharming Group NV Sijmen de Vries Chief Executive Officer Pharming Group N.V. HollandBIO September 2017 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The information contained in this document and communicated verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published, in whole or in part, for any purp
Slide 3: Overview
Overview We develop and commercialize human therapeutic proteins for • Euronext: PHARM - market capitalization: €260-290 million innovative therapies meeting important unmet • HQ and manufacturing in Netherlands, R&D in France and patient needs US commercial operations in New Jersey with approximate
Slide 4: Corporate Highlights
Corporate Highlights • Re- acquisition of US commercialisation rights from Valeant in Dec 2016 RUCONEST® • H1 2017 revenues: €30.6 million (H1 2016 revenues: €5.3 million) Commercialisation • Q1 2017 operating profit €4.2 million (H1 2016 operating loss €6.2 million ) • US data exclusivity granted u
Slide 5: The origin of Pharming
The origin of Pharming 1980 1990 1995 2008 GENPHARM & GENEPHARMING EUROPE Use of transgenesis for the production of protein therapies
Slide 6: History of Pharming
History of Pharming 1988 Business establishment: Production of proteins for pharmaceutical applications in the milk of transgenic animals 1990 Herman: The first transgenic bull 1994 First demonstration of the concept: Human proteins from cow's milk 1998 Transgenic rabbits produce rh-α-glucosidase an
Slide 7: Pipeline
Pipeline Lead Preclinical Clinical Regulatory Commercialization Optimization Development Review RUCONEST® Acute Hereditary Angioedema RUCONEST® Prophylaxis of Hereditary Angioedema Pharming will submit a Clinical Trial Results in Prophylaxis of HAE BLA supplement (sBLA) to the FDA for review RUCONES
Slide 8: US HAE Market: Rapid Growth, Significant Potential, Very Competitive
US HAE Market: Rapid Growth, Significant Potential, Very Total Market Competitive in $millions The US HAE market is expected to continue to grow 20%+ p.a. until 2020*** 2,000 HAE disease awareness in the US continues to improve with more patients seeking relief for moderate symptoms*** 1,500 Annual
Slide 9: Clinical Trial Results in Prophylaxis of HAE
Clinical Clinical Trial Trial Results Resultsin inProphylaxis ProphylaxisofofHAE HAE 9
Slide 10: rhC1INH Prophylaxis: Clinical Response With Twice Weekly Dosing
rhC1INH Prophylaxis: Clinical Response With Twice Weekly Dosing Prophylaxis with Twice Weekly rhC1INH resulted in consistent reduction of HAE attack frequency (n=23) 7 Clinical Trial Results in Prophylaxis of HAE 6 6 6 5 4 4 4 3 2 2 1 1 0 0 0 0 0 0 -1-100 0–9 10–19 20–29 30–39 40–49 50–59 60–69 70–7
Slide 11: Twice Weekly Nano-filtered pdC1INH Prophylaxis Response
rhC1INH Prophylaxis: Clinical Response With Twice Weekly Dosing Prophylaxis with Twice Weekly Nano-filtered pdC1INH (n=22) resulted in varying reduction of HAE attack frequency 5 Clinical Trial Results in Prophylaxis of HAE 4 3 4 4 3 2 2 2 2 2 1 1 1 1 0 0 -1-100 0–9 10–19 20–29 30–39 40–49 50–59 60–
Slide 12: Next Generation RUCONEST
Next Clinical TrialGeneration Results in RUCONEST® Prophylaxis of HAE 12
Slide 13: Next Generation RUCONEST
Next Generation RUCONEST • RUCONEST efficacy and safety profile for the treatment of HAE attacks is unsurpassed (on the basis of comparing published literature and patient experience) • Next step: Improving convenience of use • New highly concentrated vial in development for faster application of IV
Slide 14: Re-acquisition of North American Commercialisation Rights for RUCONEST
US Commercialisation ClinicalRe-acquisition Trial ResultsofinNorth Americanof HAE Prophylaxis Commercialisation Rights for RUCONEST® 14
Slide 15: Re-acquisition overview
Re-acquisition overview Re-acquisition of the North American Commercial Rights to RUCONEST® from Valeant on 7 • Original licensing deal in 3Q 2010 with NASDAQ-listed December 2016 Santarus for $50 million in upfront and regulatory milestones and profitable supply for 30% of US net sales, with a $45
Slide 16: Building a US Infrastructure
Building a US Infrastructure • Acquired entire Valeant sales team as part of transaction (11 people), • Expanded sales team and management, led by former senior HAE commercial executive as VP Commercial Operations • Medical Science Liaison (MSL), Patient Services, Market Access and Managed Care team
Slide 17: Attractive Growth Proposition
Pharming has an excellent Attractive Growth Proposition reputation in the HAE space, and strong support from the patients‘ associations • RUCONEST is the one and only non-blood-plasma-derived C1 inhibitor therapy and features unsurpassed efficacy and safety profile for treatments of attacks of HAE (
Slide 18: Financial Information and Outlook 2017
Financial Clinical Information Trial Results in and Outlookof Prophylaxis 2017 HAE 18
Slide 19: Financing and Capital Structure
Financing and Capital Structure • A $100 million 4 year debt facility (July 2021) with OrbiMed Advisors • Interest approximately 12%, reducing to 11% if the company reaches $100m in sales • Replaces original $40 million of debt and remainder ($40 million) of 18 months $49 million amortising converti
Slide 20: 1H 2017 Results
1H 2017 Results 6 months to 30 June 2017 2016 % Amounts in €m except per share data Change Income Statement Revenue from product sales 30.1 4.1 617% Clinical Trial Results in Prophylaxis of HAE Other revenue Total revenue 0.5 30.6 1.1 5.3 (67%) 477% Gross profit 27.0 3.2 763% Operating result 4.2 (6
Slide 21: Financial Impact of Reacquisition of North American Rights for RUCONEST
Financial Impact of Reacquisition of North American Rights for RUCONEST® 100% 2016 2017 2018 onward Operating Profit Operating Profit 65% Costs to boost Clinical Trial Results in Prophylaxis of HAE RUCONEST® Sales and Sales and infrastructure infrastructure Costs 45% Costs RUCONEST SOLUTIONS Costs R
Slide 22: Outlook for Remainder 2017
Increasing sales and Outlook for Remainder 2017 continued positive • Increasing sales and continued positive operating results operating results • Investment in the production of RUCONEST® in order to ensure continuity of supply. • Assessment of the clinical trial results for RUCONEST® in prophylaxi
Slide 23: Clinical Trial Results in Prophylaxis of HAE
s.devries@pharming.com www.pharming.com Clinical Trial Results in Prophylaxis of HAE Tickers: ENXTAM: PHARM Bloomberg: PHAR.AS 23
Slide 24: Questions?
Questions? 49 Pharming